DrugsControl Media Services
DrugsControl.org

News Detail

DCGI orders withdrawal of Olaparib for select cancer patients over safety concerns (22-05-2024)

New Delhi, 22 May 2024: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse effects on patients who have received three or more prior lines of c......
View Details

Source : Livemint
Olaparib cancer DCGI ovarian cancer breast cancer chemotherapy genetic mutations

Related News